Derivation of functional insulin-producing cell lines from primary mouse embryo culture  by Li, Guo Dong et al.
ava i l ab l e a t www.sc i enced i rec t . com
www.e l sev i e r. com/ loca te / sc r
Stem Cell Research (2009) 2, 29–40REGULAR ARTICLE
Derivation of functional insulin-producing cell lines
from primary mouse embryo culture
GuoDong Li a,⁎, Ruihua Luo a, Jiping Zhang a, Keng Suan Yeo b, Fei Xie a,
Eileen Khia Way Tan b, Dorothée Caille c, Jianwen Que d, Oi Lian Kon e,
Manuel Salto-Tellez f, Paolo Meda c, Sai Kiang Lim d,g,h,⁎a Cardiovascular Research Institute, National University Medical Institutes, Yong Loo Lin School of Medicine,
National University of Singapore, Singapore 117597
b Genome Institute of Singapore, ASTAR, Singapore
c Department of Cell Physiology and Metabolism, University of Geneva, Geneva, Switzerland
d Institute of Medical Biology, ASTAR, Singapore 138648
e National Cancer Center, Singapore
f Department of Pathology, National University of Singapore, Singapore 117597
g Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597
h School of Biological Sciences, Nanyang Technological University, SingaporeReceived 12 March 2008; received in revised form 4 July 2008; accepted 23 July 2008Abstract We have previously described the derivation of insulin-producing cell lines from mouse embryonic stem cells
(mESCs) by differentiation of an intermediate lineage-restricted E-RoSH cell line through nutrient depletion in the presence
of nicotinamide followed by limiting dilution. Here we investigated whether insulin-producing cell lines could be similarly
derived directly from mouse embryo cells or tissues. Using a similar approach, we generated the RoSH2.K and MEPI-1 to -14
insulin-producing cell lines from the 5.5-dpc embryo-derived E-RoSH-analogous RoSH2 cell line and a 6.0-dpc mouse embryo
culture, respectively. Insulin content was ∼8 μg/106 MEPI-1 cells and 0.5 μg/106 RoSH2.K cells. Like insulin-producing
mESC-derived ERoSHK cell lines, both MEPI and RoSH2.K lines were amenable to repeated cycles of freeze and thaw,
replicated for months with a doubling time of 3–4 days, and exhibited genomic, structural, biochemical, and
pharmacological properties of pancreatic β-cells, including storage and release of insulin and C-peptide in an equimolar
ratio. Transplantation of these cells also reversed hyperglycemia in streptozotocin-treated SCID mice and did not induce
teratoma. Like ERoSHK cells, both RoSH2.K and MEPI-1 cells also induced hypoglycemia in the mice. Therefore, our
protocol is robust and could reproducibly generate insulin-producing cell lines from different embryonic cell sources.
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Type 1 diabetes is a devastating disease that has no cure.
Disease management is a chronic self-monitored and self-
administered injection of insulin. Although pancreatic islet
transplantation is effective in replacing the loss of insulin-
producing β-cell mass and reversing the disease, it is limited.
30 G.D. Li et al.by a shortage of donor organs (Shapiro et al., 2000).
Therefore, embryonic stem cells (ESCs) and adult stem
cells are being investigated as alternative sources of
surrogate insulin-producing cells. We recently generated
insulin-producing ERoSHK cell lines from mouse (m) ESCs by
differentiating an intermediate mESC-derived lineage-
restricted cell line through nutrient depletion followed by
limiting dilution (Li et al., 2009). The derivation of these
lines demonstrates that ESCs are a viable cellular source for
generating homogeneous scalable quantities of insulin-
producing cells for replacement therapy of type 1 diabetes.
These cell lines circumvented several limitations in generat-
ing sufficient surrogate pancreatic β-cells from ESCs, such as
homogeneous populations of insulin-producing cells that
produce high levels of properly processed insulin, the release
of insulin in a glucose-induced and regulated manner, and a
lack of teratoma-forming potential (Colman, 2004; Halban,
2004; Bonner-Weir and Weir, 2005).
The generation of these insulin-producing cell lines from
ESCs, however, contradicts the common phenomenon ofFigure 1 Characterization of RoSH2.K cells. (a) Morphology of M
content of RoSH2.K and MEPI-1 cells relative to that of INS-1 cells. (c
release from RoSH2.K cells as a percentage of cellular insulin content
(e) Correction of hyperglycemia in streptozotocin-induced diab
streptozotocin (solid arrows) to induce hyperglycemia. When the b
were sham-operated (solid circles, n=4), transplanted subcutaneou
subcutaneously with 5×106 RoSH2.K cells followed by removal of cerapid loss in insulin-producing and replication capacities
when insulin-producing pancreatic β-cells are cultured. In
addition, they exhibit poor coupling of glucose stimulus–
insulin secretion and have elevated basal insulin secretion
rates that probably account for the hypoglycemia and
hyperinsulinemia observed in diabetic mice transplanted
with ERoSHK cells. We postulated that together these
characteristics suggest an immature rather than an adult
pancreatic islet β-cell phenotype (Aguayo-Mazzucato et al.,
2006; Li et al., 2009). We also hypothesized that this
immature state is a consequence of using embryonic parental
cells without exposing the differentiated cells to a still
poorly defined postnatal maturation process (Milner et al.,
1972; Phelps et al., 1978; Grill et al., 1981).
To test this hypothesis, and also the general robustness of
this approach in deriving insulin-producing cell lines from
embryonic tissues or embryo-derived cells, we used a similar
approach to derive similar insulin-producing cell lines from
in vitro differentiation of an embryo-derived E-RoSH-like
cell line and primary 6.5-dpc embryo culture.EPI-1, RoSH2.K, and progenitor RoSH2 cells. (b) Cellular insulin
) Molar ratio of insulin and C-peptide in RoSH2.K cells. (d) Insulin
in the presence of glucose, potassium, and forskolin over 30 min.
etic mice. SCID mice were treated with two injections of
lood glucose level exceeded 350 mg/dl (open arrow), the mice
sly with 5×106 RoSH2.K cells (triangles, n=3), or transplanted
ll grafts (asterisk) (diamonds, n=4).
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Deriving the insulin-producing RoSH2.K cell line
from embryo-derived RoSH2 cells
As the mESC-derived insulin-producing ERoSHK cell lines (Li
et al., 2009) were derived from the intermediate lineage-
restricted E-RoSH cell line (Lian et al., 2006), we investi-
gated whether similar insulin-producing cell lines could also
be isolated from analogous cell lines derived directly from
embryo, the previously described RoSH cell lines (Yin et al.,
2004). Like the E-RoSH cell lines, the RoSH cell lines do not
express pluripotency-associated markers such as Oct-4,
Sox2, Hesx, and TDGF or the neural marker, nestin
(Supplementary Fig. 1), but do express markers associated
with early mesodermal and endodermal differentiation,
e.g., mesoderm-associated genes such as Gata-4, Pdgfra,
Runx-1, and Tek-1 (Supplementary Fig. 1) and endoderm-
associated genes such as AFP, FABP2, Foxa2, HNF4a, and
Sox17 (Supplementary Fig. 1). Using a similar differentiationFigure 2 Pancreatic islet cell-like characteristics of MEPI-1 cells.
during 30 weekly passages. (b) Population doubling time of MEPI-1 ce
H and E staining (left), insulin immunoreactivity (center), and glucag
25 μm. (d) Immunoblotting analysis for mature insulin using a nonden
line and ESCs were used as positive and negative controls, respective
measured by RIA. (f) Cellular localization of insulin and C-peptide i
microscopy of subcellular morphology in MEPI-1 cells. Bar, 215 nm. (h
islets (bottom). Total RNA was assayed by RT-PCR for transcript level
pancreatic polypeptide. The bottom gel is also used in the companioand isolation approach of nutrient depletion and nicotina-
mide treatment on one of the RoSH cell lines, RoSH2, and
then limiting dilution of the differentiated RoSH2 cultures as
summarized in Supplementary Fig. 2, we isolated two cell
lines, RoSH2K-1 and RoSH2K-2, that resembled ERoSHK cells.
RoSH2K cells were morphologically distinct from their
parental RoSH2 (Fig. 1a). One line, hereafter referred to as
RoSH2.K, was further characterized. Unlike the parental
RoSH2 line, RoSH2.K cells expressed higher levels of insulin
transcripts (Supplementary Table 2) and contained ∼0.5 μg
insulin/106 cells with near-equimolar amounts of C-peptide
(Figs. 1b and 1c). Like ERoSHK cells, N90% RoSH2.K cells were
insulin immunoreactive and replicated with a similar
population doubling time of 3.1 days.
RoSH2.K cells have functional glucose-sensitive
insulin-secretion machinery
As in ERoSHK cells, there was a glucose-sensitive increase in
the rate of insulin release in RoSH2.K cells, which reached a(a) Cellular insulin content of MEPI-1 cells as measured by RIA
lls during 30 weekly passages. (c) Immunohistochemical analysis.
on immunoreactivity (right). Arrows indicate mitotic cells. Bars,
aturing Western blot of total proteins of MEPI-1 cells. The INS-1
ly. (e) Cellular content of insulin and C-peptide in MEPI-1 cells as
n MEPI-1 cells by immunofluorescence. Bar, 20 μm. (g) Electron
) Gene expression in MEPI-1 cells (top) and isolated adult mouse
s of major β-cell markers. GK, glucokinase; SS, somatostatin; PP,
n article (Li et al., 2009).
Figure 3 Detection of pancreatic islet β-cell-specific proteins
in MEPI-1 cells. (a) Western blot analysis for the presence of Pdx-
1 and glucokinase (GK) in total protein extracts from MEPI-1 cells
and also Pdx-1 in the nuclear extracts. Positive controls were
pancreatic islets, INS-1 cells, and ERoSHK-4 cells; negative
controls were mouse E14 ESCs (ES) and E-RoSH cells. (b)
Immunofluorescence analysis for the cellular localization of
glucokinase (GK) and Glut2 proteins in MEPI-1 cells.
32 G.D. Li et al.maximum at 8.4 mM glucose (Fig. 1d). Basal insulin secretion
at 2.8 mM glucose over 30 min was high at ∼4% of insulin
content, which is much higher than the typical b 1% in adult
islet cells (Flamez et al., 1998; Guenifi et al., 1998). Like
ERoSHK cells, other aspects of the glucose-induced insulin-
release machinery appeared to be intact and resembled that
of mature islet β-cells. For example, glucose-induced insulin
release in RoSH2.K cells was also markedly potentiated by
compounds that increase [cAMP]i, e.g., forskolin (Fig. 1d),
and by a high concentration of potassium (Fig. 1d).
RoSH2.K cells reverse hyperglycemia in
streptozotocin-treated hyperglycemic mice
The in vivo function of RoSH2.K cells was assessed by
subcutaneous transplantation of 5×106 cells in streptozoto-
cin-treated SCID mice with a blood glucose level exceeding
350 mg/dl. The blood glucose levels of all cell-transplanted
but not sham-operated mice decreased progressively to
reach normoglycemia within 10 days of transplantation, but
returned to pretransplant levels upon removal of the cell
grafts (Fig. 1e).
Deriving the insulin-producing MEPI cell lines from
primary mouse embryo culture
To determine if insulin-producing cell lines could be derived
directly from in vitro differentiation of primary mouse
embryo culture, we cultured 6.5-dpc mouse embryos on
mouse embryonic fibroblasts (MEFs) and induced the primary
embryo culture to differentiate as described under Materials
and Methods (Supplementary Fig. 2). One colony generated
16 lines of mouse embryo progenitor-derived insulin-produ-
cing (MEPI) cells, 14 of which had insulin contents of 0.3–
5.8 μg/106 cells (∼1.6–31.2 μg/mg protein) (Supplementary
Fig. 3). The MEPI-1 cell line, which expressed the highest
levels of insulin, was used for the experiments reported
here. MEPI-1 cells featured a stable (Fig. 2a) insulin content
(5.1–8.2 μg/106 cells) that was ∼25% that of adult islets and
a stable population doubling time of∼2.4 days (Fig. 2b). Most
MEPI-1 cells were insulin immunoreactive with b10% being
glucagon immunoreactive (Fig. 2c). They contained properly
processed insulin (Fig. 2d) in an equimolar concentration with
C-peptide (Fig. 2e), which, in the majority of the cells,
colocalized in the cytoplasm (Fig. 2f) and, more specifically,
in the cisternae of the Golgi apparatus and secretory granules
(Supplementary Fig. 4). There were some dense-core secre-
tory granules with the clear peripheral halo (Fig. 2g) but most
appeared immature and lacked the clear peripheral halo. Like
ERoSHK cells (Li et al., 2009), MEPI-1 cells also expressed
pancreatic β-cell-like genes encoding both proinsulin-1 and
proinsulin-2, Glut2, glucokinase, PC1/3, Kir6.2, Sur-1, IAPP,
IRS-2, HNF3β, Isl-1, NeuroD1, Pax-6, Nkx2.2, and Nkx6.1 (Fig.
2h) (Supplementary Fig. 5), but not genes encodingNgn3, Pax-
4, nestin, HNF1α, and Oct-4 (Smith et al., 1999; Boj et al.,
2001; Edlund, 2002; Herrera et al., 2002; Gu et al., 2002,
2003; Chakrabarti and Mirmira, 2003; Habener et al., 2005).
Glucagon but not somatostatin or pancreatic polypeptide
transcripts were also detected (Fig. 2h). Gene transcripts for
the critical pancreatic β-cell gene products Pdx-1 and
glucokinase were present (Supplementary Fig. 5) and theirprotein products were readily detectable (Fig. 3a) in the
appropriate cellular compartments, such as nucleus for Pdx-1
(Fig. 3a), cytosol for glucokinase, and plasma membrane for
Glut2 (Fig. 3b). As in normal β-cells, increasing glucose
concentration from 1 to 16.7 mM for 2 h induced an 87%
increase in proinsulin-1 mRNA levels in MEPI-1 cells. Together,
these observations demonstrate that the regulation of gene
expression in MEPI cells was qualitatively similar to that of
adult mouse islets.
MEPI cells possess a functional glucose-sensitive
insulin-secreting apparatus
The glucose-induced insulin releasemachinery appeared to be
intact in MEPI-1 cells and resembled that of mature islet β-
cells. Stimulation by glucose and sulfonylureas depolarized
MEPI-1 cells through a mechanism that was blocked by
diazoxide, a drug that opens KATP channels (Fig. 4a), and
increased intracellular free Ca2+ levels ([Ca2+]i) in MEPI-1 cells
by amechanism thatwas abrogated by verapamil, a blocker of
L-type Ca2+ channels (Fig. 4b), and diazoxide (data not
shown). Like in insulin-secreting ERoSHK and RoSH2.K cells,
therewas a glucose-sensitive increase in the rate of equimolar
insulin and C-peptide release in MEPI-1 cells, reaching a
maximum at 8.4 mM glucose (Fig. 4c). MEPI-1 cells have a
relatively high basal secretion rate of 1.5% insulin content
over 30 min at 2.8 mM glucose (Fig. 4d). Other typical β-cell
secretagogues including sulfonylureas, e.g., tolbutamide or
glibenclamide; amino acid fuels, e.g., L-leucine; and a high
concentration of potassium were also able to either stimulate
or enhance glucose-induced insulin release from MEPI-1 cells
(Figs. 4d and 4e). Like adult β-cells and our other insulin-
producing cell lines (ERoSHK cells and RoSH2.K cells), glucose-
Figure 4 Coupling of stimulus and insulin secretion in MEPI-1 cells. (a) Measurement of membrane depolarization in MEPI-1 cells in
response to 15 mM glucose, 100 μM tolbutamide, and 100 nM glibenclamide followed by opening of KATP channels by diazoxide.
Membrane depolarization was monitored using bisoxonol, a fluorescent probe. The fluorescence signal was expressed as a percentage
of the depolarization induced by 40 mM KCl. Time bar, 100 s. (b) Effects of stimulatory concentrations of glucose and sulfonylureas on
intracellular calcium concentration ([Ca2+]i) in MEPI-1 cells followed by blocking of L-type Ca
2+ channels with verapamil. [Ca2+]i was
measured using the fluorescent probe Fura-2. Time bar, 60 s. Each of the traces shown in (a) and (b) is representative of at least four
experiments. (c) Amount of insulin and C-peptide released from MEPI-1 cells in response to glucose stimulation over 30 min. (d and e)
Effects of drugs and hormones on insulin secretion in MEPI-1 cells. MEPI cells were exposed for 30 min, in the presence of 2.8, 5.6, or
8.4 mM glucose, to one of the following: KCl, 34 mM; L-leucine (Leu), 10 mM; forskolin (Frsk), 1 μM; IBMX, 100 μM; verapamil (Vera),
20 μM; diazoxide (Diaz), 200 μM; epinephrine (Epin), 1 μM; somatostatin (SS), 100 nM; tolbutamide (Tolbu), 200 μM; glibenclamide
(Gliben) 100 nM. ⁎pb0.05 and ⁎⁎pb0.01 vs 2.8 mM glucose; #pb0.01 vs 8.4 mM glucose.
33Embryo-derived insulin-producing cell linesinduced insulin release from MEPI-1 cells was markedly
potentiated by compounds that increase [cAMP]i, e.g.,
forskolin and isobutylmethylxanthine, whereas diazoxide,
verapamil, epinephrine, and somatostatin suppressed glu-
cose-induced insulin secretion fromMEPI-1 cells (Fig. 4e). This
glucose-regulated insulin release was retained throughout 30
passages of MEPI-1 cells. Together, these observations
demonstrated that the insulin secretory apparatus in MEPI
cells was generally intact and functioned molecularly, like
that of native β-cells.
Embryo-derived MEPI cells reversed hyperglycemia
in streptozotocin-treated hyperglycemic SCID mice
Kidney subcapsular or subcutaneous transplantation of
5×106 MEPI-1 cells in streptozotocin-treated diabetic SCIDmice progressively reduced blood glucose in all cell-
transplanted but not sham-operated mice to reach normo-
glycemia within 2 weeks (Figs. 5a and 5b). Removal of the
subcutaneously transplanted cell grafts reversed the blood
glucose level to pretransplant levels (Fig. 5b). The pancreas
of both cell-transplanted and sham-operated mice had fewer
and smaller pancreatic islets consisting of mainly glucagon-
containing cells (Fig. 5c) and contained significantly reduced
insulin content (Fig. 5d). The transplanted MEPI-1 cell grafts
under the kidney capsule were vascularized with abundant
insulin-containing cells and also a few glucagon-containing
cells (Fig. 5e). There were also some mitotic activity (insets
in Fig. 5e) and a high insulin content in the grafted kidneys
(Fig. 5d). After transplantation, undetectable blood insulin
levels in diabetic mice increased in excess of prediabetic
levels, and blood insulin returned to pretransplant levels on
Figure 5 Transplantation of MEPI-1 cells in SCID mice. (a) Correction of hyperglycemia in diabetic mice. SCID mice were treated with
two injections of streptozotocin (solid arrows) to induce hyperglycemia. When blood glucose level exceeded 350 mg/dl (open arrow),
mice either were transplanted with 5×106 MEPI-1 cells under the kidney capsule (n=7) or underwent a sham operation (n=6). (b)
Reversal and restoration of hyperglycemia in streptozotocin-induced diabetic SCID mice by subcutaneous transplantation and then
removal of MEPI-1 cell grafts. Hyperglycemia was induced in SCID mice by two injections of streptozotocin (solid arrows). The mice
were treated as follows: sham transplanted (circles, n=6), subcutaneous transplantation (open arrow) of 5×106 MEPI-1 cells
(triangles, n=4), and subcutaneous transplantation of 5×106 MEPI-1 cells followed by removal of cell grafts (asterisk) (diamonds,
n=4). (c) Analysis of insulin and glucagon immunoreactivities in pancreas of MEPI-cell-transplanted and sham-operated mice. Typical
pancreatic islet of normal adult SCID mouse (left), sham-operated mouse (middle), MEPI-1-cell-transplanted mouse (right). Bar,
100 μm. (d) Insulin content in pancreas of untreated mice (c.p.), pancreas of sham-operated streptozotocin-treated mice (d.p.),
pancreas of MEPI-cell-transplanted streptozotocin-treated mice (m.p.), and kidney grafted with MEPI-1 cells (m.k.). (e) Histological
analysis of renal MEPI-1 cell graft. H and E staining (left), insulin-immunohistochemical staining (middle), and glucagon-
immunohistochemical staining (right). The insets show mitotic MEPI-1 cells within the graft. Bar, 50 μm. (f) Serum insulin levels in
mice that were normal, nondiabetic (Ct), diabetic (Di), diabetic with MEPI-1 cells transplanted (Tx), or diabetic with MEPI-1 cells
transplanted and then removed (Rv). Values are means ± SEM (n=4). After subcutaneous transplantation of (g) 2×106 MEPI-1 cells for
8 weeks (n=3) or (h) mouse ESCs for 3 weeks (n=3) in SCID mice, the transplanted cell grafts were removed, fixed, paraffin-
embedded, sectioned, and stained with H and E. Arrow indicates a mitotic cell. Bar, 25 μm in (g) and 100 μm in (h).
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ERoSHK cells (Li et al., 2009) and RoSH2K cells (Fig. 1e), the
return to normoglycemia in the cell-transplanted diabetic
animals was followed by a period of sustained hypoglycemia
(Figs. 5a and 5b) that stabilized at 40–50 mg/dl. Despite
their weakened state from hypoglycemia, the cell-trans-
planted mice were viable. Subcutaneously transplanted
MEPI-1 cells in SCID mice also maintained their cellular
phenotype (Fig. 5g), in contrast to ESC, which differentiated
to form an aggressively growing teratoma (Fig. 5h).Discussion
With this study, we have effectively described a sequential
generation of insulin-producing cell lines from three dif-ferent but related cell sources starting with mESC-derived
E-RoSH cell lines (Li et al., 2009), then embryo-derived
RoSH cell lines, and finally a primary embryo culture (Fig.
6a). The differentiation and isolation protocols for these
additional lines share a common feature of using reduced
nutrient level in the medium and nicotinamide to induce
differentiation. A notable difference between the protocol
described here and that previously described (Li et al.,
2009) was that the nutrient level was reduced by
decreasing the frequency of medium change from once a
day to once a week instead of serum deprivation as
previously described. In our hands, the former took longer
to inhibit proliferation and induce differentiation and
apoptosis. The insulin-producing lines derived from these
three different cell sources were highly similar in their
morphology and other functional properties. They have
35Embryo-derived insulin-producing cell linestypical insulin storage vesicles and insulin release was
mechanistically similar to that of adult pancreatic β-cells.
Gene expression in RoSH2.K and ERoSHK cells or RoSH2.K
and MEPI cells was highly correlated with r2=0.92 and
0.62, respectively (Figs. 6b and c) and they all expressed
similar levels of Ins-1 and Ins-2 (Fig. 6d). Of the 20 mosthighly expressed genes in RoSH2.K cells, 16 genes, namely
Chgb, Camk2b, Scgn, Chga, Ins2, Slc30a8, Isl1, Pam, Pcsk2,
Scg2, Slc8a1, Tac1, Insm1, Npy, Nkx2-2, and Gnao, are
highly and/or specifically expressed in pancreatic β-cells
and are involved in the differentiation of the endocrine
pancreas and in the processing, storage, and secretion ofFigure 6 Comparison of ERoSHK, RoSH2.K, and MEPI-1 cells. (a) Schematic representation of sequential generation of insulin-
producing cell lines from three different but related cell sources: ERoSHK cell lines from mESC-derived E-RoSH cell lines, RoSH2.K
cell lines from embryo-derived RoSH cell lines, and MEPI cell lines from a primary embryo culture. (b, c) Gene expression profiles of
E-RoSHK.1, RoSH2.K, and MEPI-1 cells were determined by hybridization to the Illumina Sentrix Mouse Ref-8 Expression Bead Chip
and compared in a pairwise analysis of (b) E-RoSHK.1 and RoSH2.K and (c) E-RoSHK.1 and MEPI-1. (d) Expression of pancreatic β-cell-
specific genes (proinsulin-1 and -2) in E14 mESC, RoSH2, E-RoSH2.1, E-RoSHK.1, RoSH2.K, and MEPI-1 cells as assayed by qRT-PCR of
total RNA. The Ct value for each gene transcript level in ESCs is denoted.
36 G.D. Li et al.insulin (Supplementary Table 2). All these genes are also
highly expressed in ERoSHK and MEPI cells (Supplementary
Table 2).
Most importantly, all three groups of insulin-producing
cells reversed hyperglycemia in streptozotocin-treated mice
and also induced a state of hypoglycemia. We have previously
attributed the induction of this hypoglycemic state to an
immature developmental state of the cells (Li et al., 2009).
D20 neonatal rats were reportedly both hyperglycemic and
hyperinsulinemic, with the former being attributed to
peripheral insulin resistance and the latter to high basal
secretion of insulin and poor coupling of glucose stimulus–
insulin secretion, by which the same amount of insulin was
secreted upon exposure to 15.6 or 5.6 mM glucose (Aguayo-
Mazzucato et al., 2006). After birth, neonatal pancreatic islet
cells acquire the adult phenotype through a still poorly
defined postnatal maturation process (Milner et al., 1972;
Phelps et al., 1978; Grill et al., 1981). Thus in many aspects,
all three groups of insulin-producing cell lines resemble
immature pancreatic β-cells. They exhibited a higher basal
insulin secretion of 1 to 4% compared to the typically much
less than 1% observed in adult islet cells (Flamez et al., 1998;
Guenifi et al., 1998), continued to proliferatewhile producing
insulin, and displayed poor coupling of glucose stimulus–
insulin secretion. All our insulin-producing cell lines also
resembled immature pancreaticβ-cells in neonatal rats to the
extent that they induced hyperinsulinemia (Fig. 5f) (Li et al.,
2009) when transplanted into mice. As the cells were
transplanted into adult animals, which, unlike neonatal
animals, have no peripheral insulin resistance, the hyper-
insulinemia induced hypoglycemia in these animals.
We noted, however, that the induction of this hypogly-
cemic state by our cell lines could also be attributed to
“insulinoma” characteristics. Insulinoma cells are known to
induce hypoglycemia as a result of uncontrolled growth
resulting in hyperinsulinemia (Vozzi et al., 1997). Consistent
with this hypothesis is our observation that all the insulin-
producing cell lines are karyotypically abnormal. Briefly, the
chromosome number in ERoSHK cells is 36–40 (Li et al.,
2009), in RoSH2K cells is ∼39–40, and in MEPI cells is about
60–70 (Supplementary Fig. 6). Based on our experience of
maintaining a normal karyotype in mouse ESC cultures by
periodically having to subclone mESCs and select karyotypi-
cally normal clones (Li et al., 2009), we postulated that the
abnormal karyotypes in all the cell lines are probably due to
the inherently unstable karyotype of mouse cells and the
extended in vitro propagation of the cells to induce
differentiation and then to select and expand the insulin-
producing clones. Consistent with this, MEPI cell lines, which
were derived from a primary embryo culture and not a
selected clonal cell line and were subjected to a much longer
in vitro manipulation, have the most apparent chromosomal
abnormalities among the three groups of insulin-producing
cell lines. Although it is possible that these different
chromosomal abnormalities fortuitously induced a similar
phenotype change in all three groups of cell lines that
included a wide spectrum of gene expression and cellular
functions found in adult pancreatic β-cells, the different
chromosomal abnormalities in all the cell lines and the
inherent chromosomal instability of mESCs suggest that the
insulin-producing cell lines were generated despite these
chromosomal abnormalities and not as a consequence ofthem. However, the abnormal karyotype in all the cell lines is
an important issue that has to be resolved. It is not clear if
this issue is unique to our approach or if this is a more
generalized problem associated with the prolonged culture
necessary to generate terminally differentiated cell types
from in vitro differentiation of either ESCs or adult stem
cells. This issue has hitherto never been experimentally
addressed, possibly because to date, no such in vitro-
differentiated cell types have been prepared in sufficient
purity or quantity to permit karyotype analysis.
In addition to the abnormal karyotype, our insulin-
producing cell lines also possessed other characteristics
associated with insulinoma cells, namely continued prolif-
eration of the cell lines and induction of hypoglycemia in
rodents. There were, however, significant differences.
Insulinoma cells are known to induce hypoglycemia primarily
through the formation of a large cell mass that secretes a
large amount of insulin. It was previously reported that
subcutaneous injection of 1×106 INS-1 insulinoma cells into
rats initially induced a slow gradual decline in blood glucose
after week 2. After week 3, this decline increased linearly
and exponentially to less than 30 mg/dl and this paralleled
the growth rate of the cell grafts that generally formed large
1-cm tumors by week 5 (Vozzi et al., 1997). We also observed
a similar phenomenon when we subcutaneously implanted
5×106 insulinoma INS-1 cells in SCID mice. At day 30, the
implanted cells formed tumors of 0.8–0.9 cm and induced
such severe hypoglycemia (20 mg/dl) that the mice had to be
euthanized. In sharp contrast, both RoSH2K and MEPI cells,
like ERoSHK cells (Li et al., 2009), induced an exponential
decline in blood glucose level within days of the transplant to
reach normoglycemia before declining gradually to stabilize
at a hypoglycemic glucose level of 40–50 mg/dl (Figs. 1e and
5b). Unlike INS-1-transplanted mice, these hypoglycemic
mice were viable. In addition, transplantation of RoSH2K
cells induced hypoglycemia with kinetics similar to that of
MEPI-1 cell transplantation, despite having about a tenth of
the insulin content of MEPI-1 cells (Fig. 1b). The in vivo
growth of RoSH2K and MEPI cells was also relatively slower
than that of INS-1 cells. As a comparison, subcutaneous
transplantation of 2×106 mESC in SCID mice formed a cell
mass of about 0.5×0.5 cm on day 10 and 1×1.2 cm on day 16,
while similar transplantation of 10×106 MEPI-1 cells formed a
visible cell mass of 0.2×0.3 cm only on day 16 and
0.3×0.4 cm on day 30. The growth of MEPI cells was
comparable to that of ERoSHK cells, which took 50 and
75 days for these grafts to reach diameters of 2–3 and 3–
3.5 mm, respectively (Li et al., 2009). Therefore, the rapid
decline in blood glucose levels and the subsequent induction
of hypoglycemia by RoSH2K and MEPI-1 cell transplantation
did not correlate with the size and insulin content of the cell
grafts and cannot be attributed to the formation of large cell
masses, such as insulinomas, that collectively released a
large volume of insulin. It remains to be determined if our
insulin-producing cells resemble insulinoma cells or imma-
ture β-cells that could be induced to mature into adult
pancreatic islet β-cells. We note here that transplantation of
pancreatic endocrine cells derived from karyotypically
normal hESCs into streptozotocin-induced diabetic SCID
mice also induced hypoglycemia (Kroon et al., 2008). Taken
together, this and our findings suggest that induction of
hypoglycemia may be a common feature of insulin-producing
37Embryo-derived insulin-producing cell linescells derived from in vitro differentiation of embryonic
progenitors and that this feature may be unrelated to
karyotype changes.
In conclusion, the derivation of similar insulin-producing
cell lines from three different but related sources using similar
differentiation protocols demonstrated the robustness and
reproducibility of our approach in deriving insulin-producing
cell lines.More importantly, it suggests that the differentiation
involved a mechanistically conserved pathway. The derivation
of MEPI cell lines from a primary embryo culture instead of
embryo-derived cell lines further implied that this pathway is
physiologically relevant and may reflect some aspects of
embryonic pancreatic endoderm development. Therefore,
this approach to generating insulin-producing cell lines could
be used as a surrogate model system to dissect molecularly
embryonic pancreatic endoderm development. This could
potentially provide an insight into the process of generating
therapeutically useful insulin-producing cell lines from human
embryonic stem cells or embryonic tissues.
Materials and Methods
Derivation of RoSH2.K cell line
Fifty thousand cells from the RoSH2 line that was derived
from 5.5-dpc delayed blastocyst (Robertson, 1987; Yin et al.,
2004) were seeded (day 0) in six-well plates and cultured in
RPMI 1640 medium containing 1 mM sodium pyruvate, 50 μM
2-mercarpetoethanol, 10 mM Hepes, and 10% FBS (INS
medium) (Asfari et al., 1992). The culture medium was
refreshed once a week, and at day 17 the medium was
supplemented with 1:50 B27 (Gibco, Grand Island, NY, USA)
and 10 ng/ml bFGF for 4 days. At day 21, the cells were
cultured in INS medium supplemented with 1:50 B27 and
10 mM nicotinamide. At day 24, the cells were trypsinized
and reseeded at limiting dilution to isolate insulin-producing
RoSH2K cell lines.
Derivation of MEPI cell lines
Transient mouse E6.5 embryo cultures were prepared using
a similar approach for deriving RoSH2 cell lines (Robertson,
1987; Yin et al., 2004), except that we did not attempt to
isolate or clone putative RoSH-like cells. Briefly, E6.5 mouse
embryos from time-mated C57BL/6J female mice were
removed from the uterine horns. The egg cylinder was
dissected out and cultured with the extraembryonic tissues
in DMEM with 20% FCS on a MEF feeder layer for 2 days. The
extraembryonic tissues were removed when the egg
cylinder had attached to the culture dish. The culture,
which comprised several cell types, was repeatedly pas-
saged by trypsinizing and replating on gelatin-coated plates
until colonies of steadily dividing and morphologically
similar cells formed. Fifty thousand of these cells were
then seeded (day 0) in six-well plates and treated as
described above. At day 24, the cells were trypsinized and
reseeded in six-well plates (which was defined as passage
1). These polyclonal cell lines, hereafter referred to as MEPI
cells, were maintained in INS and were passaged every 4–
7 days in 75-cm2 culture flasks, with a change of medium
every 3 days.Isolation of islets
Islets of Langerhans were isolated from the pancreas of
adult C57BL/6J mice by perfusing collagenase through
pancreatic duct and then separating the disaggregated
pancreatic cells on Ficoll gradient centrifugation as
described (Wollheim et al., 1990). Samples of liver were
obtained from adult C57BL/6J mice. Mouse ES14 cells were
maintained in an undifferentiated state as previously
described (Robertson, 1987). Insulin-secreting INS-1 cells
were cultured as described previously (Asfari et al., 1992).
Measurement of insulin and C-peptide secretion
Insulin secretion was determined as described previously
(Li et al., 2000; Li et al., 2004). Cells were seeded in 24-
well plates and cultured for 3–4 days. After two washes
with Krebs–Ringer–Hepes buffer (KRB) containing 129 mM
NaCl, 4.8 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 5 mM NaHCO3, 2.8 mM glucose, and 10 mM Hepes,
pH 7.4, the cells were preincubated for 30 min in 0.5 ml
KRB at 37°C. Subsequently, the medium was replaced by
0.5 ml KRB containing 2.8 mM glucose (for basal secretion),
with or without additional test agents, and the cells were
incubated for another 30 min. The supernatants were
removed for measurements of secreted insulin and C-
peptide, whereas the attached cells were extracted by
acid–ethanol for insulin and C-peptide content. Insulin and
mouse C-peptide were assayed using radioimmunoassay
kits (Linco Research, St. Charles, MO, USA). The results of
insulin and C-peptide secretion were expressed as nano-
moles per million cells or as a percentage of insulin
content, to correct for any difference in the number of
cells per well.
Histology
Pieces of tissue and cytospun preparation of cells were fixed
in 10% formalin for 24 to 48 h, dehydrated, embedded in
paraffin, sectioned, and then processed for either conven-
tional hematoxylin and eosin (H and E) staining or for
immunohistochemistry (IHC). For IHC, primary antibodies
(Dako, Carpinteria, CA, USA) included a guinea pig serum
against insulin and a rabbit serum against glucagon.
Biotinylated secondary antibodies and the ABC enzyme
complexes were purchased from Vector Laboratories (Bur-
lingame, CA, USA). Slides were examined under light
microscopy.
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
Total RNA in cells and control pancreatic islets was
extracted and purified using the RNeasy Mini Kit 250
(Qiagen, Hilden, Germany) and quantified by UV spectro-
photometry. The purified RNA (250 ng per sample) was
converted into cDNA by M-MLV reverse transcriptase
(Promega) and amplified by PCR in a Thermocycler
(Biometra), using Taq DNA polymerase (Promega). The
conditions of the PCR were an initial denaturation at 94°C
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for 30 s, annealing of primers to target DNA fragments at
55–65°C for 45 s, and elongation of the complementary
strand at 72°C for 1 min. To minimize RT-PCR artifacts
from genomic DNA contamination, we designed intron-
spanning primers where possible, treated all RNA samples
with 27 units DNase I (Qiagen) during RNA purification,
and performed PCR controls on RNA samples without RT
treatment. The primers and the PCR conditions for each
primer set are summarized in Supplementary Table 1.Quantitative RT-PCR
Quantitative RT-PCR was performed using SYBR Green I-based
PCR, TaqMan Low Density Array (Applied Biosystems, Foster
City, CA, USA), or custom-designed PCR arrays (SuperArray,
Frederick, MD, USA).
For assaying the levels of the proinsulin-1 transcript in
MEPI-1 cells in response to glucose, the cells were cultured in
the presence of 1 mM glucose for 24 h, followed by a 2-h
exposure to either 1 or 16.7 mM glucose. Total RNA was then
extracted from the cells, and a minimum aliquot of 500 ng
was reverse transcribed to cDNA. The cDNA was amplified
and quantified in a real-time PCR machine (ABI Fast 7500),
using SYBR Green I as the probe. Quantitative results were
generated by the 7500 Fast System SDS software, which
calculated the relative gene expression levels compared to
that of β-actin, which was used as internal control.
The expression level of transcription factors in MEPI-1,
mouse ES, and RoSH2 cells was compared by quantitative RT-
PCR using a TaqMan Low Density Array (Applied Biosystems).
Total RNA was extracted from the cells with Trizol Reagent
(Gibco BRL) and purified over a spin column (Nucleospin RNA
II System; Macherey-Nagel GmbH, Düren, Germany) accor-
ding to the manufacturer's protocol. One microgram of total
RNA was converted to cDNA with random primers in a 50-μl
reaction volume using a High Capacity cDNA Archive Kit
(Applied Biosystems). The cDNA was diluted with distilled
water to a volume of 100 μl. One microliter per primer set
was used for the TaqMan Low Density Array according to the
manufacturer's instructions (Applied Biosystems). The Taq-
Man primer ID for each gene analyzed was Pou5f1—
Mm00658129_gH, Sox2—Mm00488369_s1, Hesx1—
Mm00439312_g1, Tdgf1—Mm00783944_g1, Gata4—
Mm00484689_m1, Pdgfra—Mm00440701_m1, Runx1—
Mm00486762_m1, Tek—Mm00443242_m1, Afp—
Mm00431715_m1, Fabp2—Mm00433188_m1, Foxa2—
Mm00839704_mH, Hnf4a—Mm00433964_m1, Sox17—
Mm00488363_m1, abcc8 (sur1)—Mm00803450_m1, Glucagon—
Mm00801712_m1, S s t—Mm00436671_m1, K i t—
mm00445212_m1, and Abl—mm01259683_g1.
Microarray analysis of gene expression profile
Total RNA (2 μg) from two biological replicates of RoSH2,
RoSH2.K, MEPI-1, E-RoSH, and ERoSHK cells was converted to
biotinylated cRNA using the Illumina RNA Amplification Kit
(Ambion, Inc., Austin, TX, USA) according to the manufac-
turer's directions. Samples were purified using the RNeasy kit
(Qiagen, Valencia, CA, USA). Hybridization to the Sentrix
MouseRef-8 Expression BeadChip holding ∼24,000 uniquegene probes (Illumina, Inc., San Diego, CA, USA), washing,
and scanning were performed according to the Illumina
BeadStation 500×manual. The data were extracted, normal-
ized, and analyzed using Illumina BeadStudio provided by the
manufacturer. Transcript signals that were below the limit of
detection at 99% confidence were eliminated as genes not
expressed.
Immunofluorescence staining
MEPI-1 or other cell types cultured on coverslips for 3–
4 days were washed twice in PBS (pH 7.4) and fixed for
10 min at room temperature in 3.7% paraformaldehyde in
PBS. Following two washes in PBS, the cells were permea-
bilized by a 10-min incubation in PBS containing 0.2%
saponin (Sigma). After a 30-min blockade in PBS containing
20% normal serum (from goat, swine, or rabbit, whichever
was relevant), the coverslips were incubated for 1.5 h at
room temperature with an antibody against the target
protein (insulin, mouse C-peptide, glucokinase, or Glut2) in
PBS supplemented with 1% BSA. After two washes, the
coverslips were incubated with an appropriate FITC- or
TRITC-conjugated second antibody for 45 min. Thereafter,
coverslips were washed and mounted on glass slides with
FluorSave reagent (CalBiochem). Samples were examined by
laser confocal microscopy (Olympus IX 70 Fluoroview300).
For each immunostaining, negative controls included: (1)
use of various dilutions of the primary antibody, (2) exposure
to a nonimmune serum, (3) incubation with only the
secondary antibody, and (4) use of tissues and cells known
to lack the protein of interest. None of these controls
resulted in a specific staining of the cells and tissues we
studied.
Electron microscopy
Conventional and immune electron microscopy studies were
performed as described previously (Li et al., 2009).
Immunoblotting
Whole cellular protein samples were obtained by sonicating
cells and other tissues in RIPA buffer. Nuclear proteins were
extracted as previously described (Wang et al., 2001).
Standard immunoblotting procedures were used. Twenty
micrograms of supernatant was denatured, separated on a
10% SDS–polyacrylamide gel, and electroblotted onto a PVDF
membrane. Themembrane was incubated sequentially with a
primary antibody followed by a relevant horseradish pero-
xidase-conjugated secondary antibody (Santa Cruz Biotechno-
logy, Santa Cruz, CA, USA). Immunoreactive bands were
visualized using the enhanced chemiluminescence (ECL)
system (Pierce Chemicals, Rockford, IL, USA). Primary
antibodies used were 1:100 dilution of anti-pdx-1 and 1:200
dilution anti-glucokinase (Santa Cruz Biotechnology); second-
ary antibodies were HRP-conjugated goat anti-rabbit, rabbit
anti-goat, and rabbit anti-mouse IgG.
A Tris–Tricine system was used to assess the insulin
maturation by immunoblotting. Briefly, 20-μg protein
samples were denatured for 5 min at 95°C in 0.1 M Tris–
HCl (pH 6.8) containing 24% v/v glycerol, 8% SDS, and
39Embryo-derived insulin-producing cell lines0.002% Coomassie Blue G-250 and separated by electro-
phoresis on 10% polyacrylamide gels (adding 10% v/v
glycerol to the separating gel). After being transferred
to a PVDF membrane, the proteins were probed with an
antibody against insulin (Linco), diluted 1:500. A horse-
radish peroxidase-conjugated goat anti-guinea pig IgG at a
1:5000 dilution (Santa Cruz Biotechnology) was used as
secondary antibody.
Measurements of membrane potential and [Ca2+]i
Membrane potential was measured by using a fluorescent
probe. About 2×106 cells were incubated with 100 nM
bisoxonol in serum-free KRB and fluorescence signal was
monitored by a spectrofluorometer (Perkin–Elmer LS-50B) at
excitation and emission wavelengths of 540 and 580 nm,
respectively. Bisoxonol signals were expressed as a percen-
tage of that observed in the presence of 40 mM K+, which
induced a maximal depolarization (Li et al., 2000; Li et al.,
2004). [Ca2+]i was determined using the fluorescent probe
Fura-2, as described previously (Li et al., 2000; Li et al.,
2004).
Animal experiments
All animal experiment procedures were approved by the
institutional IACUC. Six- to eight-week-old SCID mice were
given two ip doses (125 mg/kg) of freshly prepared strepto-
zotocin (Sigma) in 100 mM sodium citrate buffer, pH 4.5, 2–
3 days apart. When blood glucose exceeded 350mg/dl, 5×106
cells were implanted under the kidney capsule (MEPI-1 cells)
or subcutaneously in a front leg (MEPI-1 or RoSH2.K cells).
After 9 weeks, the grafted kidney and the pancreas were
taken for histological examination. For some mice that were
subcutaneously transplanted with the cells, the cell grafts
were surgically removed about 2 weeks after transplantation,
and the mice continued to be monitored for a few more
weeks. Blood glucose, body weight, and serum insulin levels
were monitored before and after cell transplantation or after
removal of the grafts.
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